Protagenic Therapeutics Inc (NASDAQ: PTIX) is a clinical-stage biopharmaceutical company focused on developing neuropsychiatric therapeutics. The company has no approved products and generates no product revenue, funding operations entirely through equity and debt financings as disclosed in its 10-K filed 2025-03-31. The filing excerpts provided do not contain sufficient detail to characterize its pipeline assets, lead compounds, therapeutic targets, competitive position, clinical stage, management team, founding year, or capital structure beyond the pre-revenue stage designation. Additional filing content would be required to describe the business with the specificity this format demands.

Source: SEC 10-K, filed 2025-03-31

Industry: Pharmaceutical Preparations Peers: Bone Biologics Corp American CryoStem Corp NeuBase Therapeutics, Inc. Ernexa Therapeutics Inc Plus Therapeutics Inc CervoMed Inc Skye Bioscience Inc Aixcrypto Holdings Inc